ALG14: A Drug Target / Disease Biomarker (G199857)

Target Name: ALG14

NCBI ID: G199857

ALG14

ALG14: A Drug Target / Disease Biomarker

ALG14 is a protein that is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the T-cell antigen receptor (TAR) family, which is a group of proteins that play a critical role in the immune system.

One of the functions of ALG14 is to interact with the protein PD-L1, which is a negative regulator of the immune response. When PD-L1 is expressed in immune cells, it can prevent those cells from activating and carrying out their normal functions. In diseases where the immune system has an imbalance, such as cancer, this can lead to an overreactive and dangerous immune response.

Research has shown that ALG14 can be targeted by small molecules, which can inhibit its activity and disrupt its interactions with PD-L1. This has led to the potential of ALG14 as a drug target or biomarker for a variety of diseases, including cancer.

One of the advantages of targeting ALG14 is that it is a protein that is expressed in a wide range of tissues, which makes it a promising candidate for a drug that can be used across different diseases. Additionally, its interactions with PD-L1 make it a good candidate for a drug that can target this protein and disrupt its function in the immune system.

Another promising aspect of ALG14 is its role in cancer progression. Many studies have shown that high levels of ALG14 are associated with poor prognosis in cancer patients. Additionally, ALG14 has been shown to promote the growth and survival of cancer cells in cell culture and animal models.

In addition to its potential as a drug target or biomarker, ALG14 has also been shown to have potential as a diagnostic biomarker. Studies have shown that ALG14 is expressed in a variety of tissues and that it is highly stable in these tissues. This makes it a promising candidate for use as a diagnostic protein for a variety of diseases.

Overall, ALG14 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its interactions with PD-L1 and its expression in a wide range of tissues make it a promising candidate for use in a variety of settings. Further research is needed to fully understand its potential and to develop safe and effective drugs or diagnostic tools based on it.

Protein Name: ALG14 UDP-N-acetylglucosaminyltransferase Subunit

Functions: Involved in protein N-glycosylation. May play a role in the second step of the dolichol-linked oligosaccharide pathway. May anchor the catalytic subunit ALG13 to the ER

The "ALG14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALG14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets